 Bellerophon Therapeutics, Inc. BLPH, a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, announced that it will host an investor conference call and webcast on the INOpulse inhaled nitric oxide system iNO for the treatment of COVID-19 at 1:00 PM EDT. The event will feature a presentation by Fabian Tenenbaum, Chief Executive Officer of Bellerophon Therapeutics, and Hunter Gillies, M.D., Chief Medical Officer of Bellerophon Therapeutics, who will discuss the Companys emergency expanded access program for INOpulse for COVID-19, through which the first patient initiated treatment. Bellerophon Therapeutics is currently developing INOpulse for multiple cardiopulmonary indications. 